IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Drewery, et al.						
International App. No.:	PCT/US2004/023680	Group Art Unit:					
International Filing Date:	July 23, 2004	Examiner:					
For:	CHEMICAL COMPOUNDS						
Commissioner for Paten Washington, D.C. 2023							
	INFORMATION DIS	SCLOSURE STATEMENT					
		on Form PTO-1449 appended hereto be considered by the with the provisions of 37 CFR 1.97					
[X] A copy of the Int PCT/US2004/02 Report are listed	erences were submitted in pa ernational Search Report wh 3680 is submitted herewith.	arent application Serial No (37 CFR 1.98(d)) nich issued on International Application No. All of the publications cited in the International Search 449 and Applicants understand that copies have been supplied Bureau.					
filing da applicat occurs l	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
of a firs		ment submitted herewith is being filed before the mailing ing of a Request For Continued Examination under 37					
filing date of an internatio event occurr (1) a fi	f the above application or the nal application or after the ned last, but before the mailinal action under § 1.113 or otice of allowance under § 1						
Statement w	as cited in a communication	of information contained in this Information Disclosure from a foreign patent office in a counterpart foreign prior to the filing of this statement.					
	cts the option to pay the fee atement under § 1.97(c) (\$24	set forth in 37 CFR 1.17(p) for submission of an Information 40.00).					

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action und 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of issue fee. Also enclosed is a copy of the International Search Report which Issued on Internation Publication No.					
	In acco	rdance with the requirements of 37 CFR 1.97(d):					
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.					
	[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).					
	[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.					
[X	-	charge any required fees to Deposit Account No.07-1392.					

Respectfully Submitted,

Kathyn L. Coulte

Kathryn L. Coulter Attorney for Appliant

Registration No. 45,889

Date: 1/25 /2006

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1467 Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PR60418USW APPLICANT Drewery et al.		INTERNATIONAD 4 (APP.NO. PCT/US2004/023680		
					INTERNATIONAL FILING DATE 7/23/04			GROUP
			U.S. PA	ATENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date	Name		Class	Subclass	Filing Date If Appropriate
	1	6,001,865	12/14/99	Silvestrini et al.				
	<u> </u>		Co	ntinue on p	page			
					T DOCUMENTS	S		
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
	2	99/06375	2/11/99	PCT				
	ļ							
	1	<u> </u>	Co	ntinue on p	oage		1	<u> </u>
	Oī	THER DOCUME				Date, Page Nu	mber, Etc.)	
·	3				on of 3-iodoindaz nes," <u>Teatrahedro</u>			
					· · · · · · · · · · · · · · · · · · ·			
	+							

	1							
	1		Co	ontinue on	page			
EXAMINER				DATE CONSIDERED				
		itial if citation co	·				•	
through citapplicant.	ation i	f not in conforma	nce and not con	sidered. In	clude copy of the	is torm with n	ext communica	ition to the